Utility of circulating tumor DNA for detection and monitoring of endometrial cancer recurrence and progression

Short title: Detection of EC recurrence and progression using ctDNA

Esther L. Moss[1,2], Diviya N. Gorsia[1], Anna Collins[1], Pavandeep Sandhu[1], Nalini Foreman[1], Anu Gore[2], Joey Wood[2], Christopher Kent[2], Lee Silcock[3], David S. Guttery[1]

[1]Leicester Cancer Research Centre, College of Life Sciences, University of Leicester, Leicester, LE2 7LX, UK.

[2]Department of Gynaecological Oncology, University Hospitals of Leicester NHS Trust, Leicester General Hospital, Leicester, LE5 4PW, UK.

[3]Nonacus Limited, Birmingham Research Park, Birmingham, B15 2SQ, UK

Corresponding authors:

Dr Esther Moss PhD FRCOG

Leicester Cancer Research Centre, University of Leicester, Leicester, LE1 7RH, UK

Tel: +44 (0)116 252 3170 Fax: +44 116 258 8210 Email: em321@leicester.ac.uk

and

Dr David Guttery PhD

Leicester Cancer Research Centre, University of Leicester, Leicester, LE1 7RH, UK

Tel: +44 (0)116 252 3170 Fax: +44 116 258 8210 Email: dsg6@leicester.ac.uk

ABSTRACT

Despite the increasing incidence of endometrial cancer (EC) worldwide and the poor overall survival of patients who recur, no reliable biomarker exists for detecting and monitoring EC recurrence and progression during routine follow-up. Circulating tumor DNA (ctDNA) is a sensitive method for monitoring cancer activity and stratifying patients that are likely to respond to therapy. As a pilot study, we investigated the utility of ctDNA for detecting and monitoring EC recurrence and progression in 13 patients using targeted next-generation sequencing (tNGS) and personalized ctDNA assays. Using tNGS, at least 1 somatic mutation at a variant allele frequency (VAF) >20% was detected in 69% (9/13) of patient tumors. The four patients with no detectable tumor mutations at >20% VAF were whole exome sequenced, with all four harboring mutations in genes not analyzed by tNGS. Analysis of matched and longitudinal plasma DNA revealed earlier detection of EC recurrence and progression and dynamic kinetics of ctDNA levels reflecting treatment response. We also detected acquired high microsatellite instability (MSI-H) in ctDNA from one patient whose primary tumor was MSI stable. Our study suggests that ctDNA analysis, and in particular MSI analysis in ctDNA could become a useful biomarker for early detection and monitoring of EC recurrence and progression.

Keywords: Endometrial cancer; Circulating tumor DNA; Digital droplet PCR; Ion Torrent; Whole exome sequencing.

47 **INTRODUCTION**

48 Endometrial cancer (EC) is the second most common female cancer in the US, with over 60,000
49 women diagnosed each year [1]. In contrast to the high survival rate in patients with primary
50 disease, the prognosis upon recurrence is poor, with a 5-year survival rate in patients with distant
51 recurrence of 17% [2, 3], and the majority of EC recurrences in high-risk cases developing distant
52 metastases within the first 3 years post-treatment [4]. There is no specific blood protein
53 biomarker that is recommended for use following an EC diagnosis; instead, regular clinical
54 examination is advised with imaging. The ovarian cancer markers CA125 and HE4 have been
55 shown to significantly correlate with prognosis; however, their detection rates in metastatic
56 disease are low, 54% and 75% respectively, and even lower with local recurrence, 39% and 16%
57 [5]. Hence, more effective biomarkers are required that can detect EC recurrence and disease
58 progression earlier, as well as reliably reflecting the underlying kinetics of the disease.

59

60 Cell-free DNA (cfDNA) can be extracted from plasma and the tumor-derived fraction of cfDNA,
61 known as circulating tumor DNA (ctDNA) is rapidly becoming a quick and sensitive biomarker
62 for tracking minimal residual disease and accurately reflecting therapeutic response in patients
63 with actionable hotspot mutations [6, 7], chromosomal rearrangements [8], and gene
64 amplifications [9, 10]. Although many studies have shown the ability of ctDNA for tracking and
65 monitoring disease in cancers such as lung [11], breast [12] and colon cancer [13], few studies
66 have highlighted its promise in EC. CtDNA has been detected in 18% of primary ECs using next-
67 generation sequencing [14], as well as showing elevated levels 6 months before a rise in CA125
68 or radiological evidence of recurrence on CT imaging in gynecological cancers [15]. However,
69 to date evidence is sparse highlighting the utility of ctDNA for detecting EC recurrence and
70 monitoring treatment response during routine follow-up. Here, we used a combination of
71 methods including targeted next-generation sequencing (tNGS), personalized ctDNA NGS

72 analysis and digital droplet PCR (ddPCR) with the primary objective of detecting and monitoring
73 EC recurrence and therapeutic response.
74
75 **METHODS**
76 The study was approved by the Wales Research Ethics Committee 7 (17/WA/0342). All patients
77 gave written informed consent prior to participation for use of their blood and tissue samples.
78 Patients were recruited to the study if they were over the age of 18 and attending hospital follow-
79 up appointments after an EC diagnosis, either after completion of primary treatment or after
80 disease relapse. The reporting census date for this study was 15th September 2019.
81
82 ***Extraction and quantitation of DNA***
83 Blood sampling and processing was performed as previously described [16]. Total cell-free DNA
84 (cfDNA) was isolated from at least 3 mL of plasma using the QIAamp Circulating Nucleic Acid
85 Kit (Qiagen) or using the MagMAX Cell-Free DNA Isolation Kit (Thermofisher) in combination
86 with the Kingfisher Flex System (Thermofisher) in an automated manner according to
87 manufacturer's instructions. cfDNA levels (ng/mL) were converted to copies/mL plasma
88 assuming 3.3 pg DNA per haploid genome. Isolation of DNA from lymphocytes and quantitation
89 of total cfDNA was as described previously [16]. FFPE tumor DNA was extracted from 1.5 mm
90 tissue cores using the Qiagen GeneRead Kit according to manufacturer's instructions.
91
92 ***Targeted next generation sequencing***
93 Targeted NGS was performed on 20 ng of FFPE tumor DNA and lymphocyte DNA, and at least
94 5 ng of cfDNA (range 5 – 50 ng) using the Oncomine™ Pan-cancer cfDNA assay (Thermofisher
95 – 52 genes covering >900 COSMIC mutations and 12 CNV regions). Libraries were prepared
96 using the Ion Chef and sequenced on Ion 540 chips using the Ion S5 XL according to

97 manufacturer's instructions to a minimum average read depth of at least 10,000x. Sequencing
98 data was accessed through the Torrent Suite v5.6 and analyzed using Ion Reporter v5.6. For
99 FFPE and lymphocyte DNA, the Oncomine TagSeq Pancan Tumor w1 workflow was used. For
100 cfDNA, the Oncomine TagSeq Pancan Liquid Biopsy w1 workflow was used. Initially, targeted
101 NGS using the Oncomine™ Pan-Cancer cfDNA assay was conducted to identify the somatic
102 mutations present in the primary tumor tissue in all cases; in two cases additional biopsies from
103 metastatic and recurrent disease were also sequenced.
104
105 ***Digital droplet PCR***
106 Droplet digital PCR (ddPCR) was performed to analyse the *TP53* p.Y220C mutation (assay
107 numbers dHsaCP2500536 and dHsaCP2500537; Bio-Rad Laboratories) and *KRAS* p.G12D
108 mutation (assay numbers dHSaCP2000001 and dHsaCP2000002) according to manufacturers'
109 instructions. Thermal cycling conditions were: 10-minute hold at 95 °C, 40 cycles of 95 °C for
110 15 seconds and then 55 °C for 60 seconds. Raw fluorescence amplitude was analyzed using the
111 Quantasoft version 1.6.6.0320 software (Bio-Rad Laboratories) [17].
112
113 ***Whole exome sequencing and personalized ctDNA sequencing***
114 The Cell3 Target Whole exome kit (Nonacus Ltd, Birmingham) and Illumina NextSeq500 was
115 used to perform whole-exome sequencing on 150-200 ng of tumor DNA from each FFPE
116 primary tumor block and 50ng of germline DNA at an average read depth of 200x for tumor
117 DNA and 50x for matched lymphocyte samples. Personalized ctDNA panels were developed for
118 analysis of at least 2 SNVs per patient (Table S1) using at least 5 ng of cfDNA (range 16 – 25
119 ng). Libraries were prepared using the Cell3™ Target Custom Panel (Nonacus Ltd, Birmingham,
120 UK) and sequenced using an Illumina MiSeq to a minimum depth of 30,000x.
121

122

123 ***Bioinformatic analysis***

124 BAM files from whole exome sequencing or personalized ctDNA assays were prepared using an
125 in-house pipeline to process sequencing output after demultiplexing. The BAM files were then
126 aligned to human genome reference 38 (GRCh38). Somatic variants arising from WES were
127 called using two variant callers, Platypus [18] and Mutect2 [19] whilst variants detected in
128 cfDNA using the personalized cfDNA assay were called using solely Platypus. Variants were
129 called using a minimum base quality and minimum mapping quality of 20, with a minimum of
130 1 read fitting these parameters for variants to be identified. Additionally, variants were filtered
131 for those with an 11-base window around to the variant location to check for variants with a
132 minimum quality < 15. The output VCF files were annotated using ANNOVAR [20] to identify
133 and annotate the subsets and variants. Microsatellite instability was analyzed using MSIsensor
134 [21] for detection of mononucleotide repeats at several genomic sites (BAT-25, BAT-26, NR-
135 21, NR-24 and NR-27) in tumor alleles as determined by a shift in ≥3bp in each marker. MSI-
136 high tumors were defined as those with ≥2 unstable markers, whilst samples with 1 unstable
137 markers were classified as MSI low tumors and those with 0 unstable markers were classified as
138 microsatellite stable (MSS).

139

140 **RESULTS**

141 In total, a cohort of 13 cases of mixed risk and mixed histology were analyzed. At the reporting
142 census date, six patients had recurred/progressed, three had died (two of their disease and one of
143 a non-EC cause) and four patients were clinically well with no clinical or radiological sign of
144 recurrence/progression (Table 1).

145

146 ***Sequencing of primary tumors***

147 Initially, targeted NGS using the Oncomine™ Pan-Cancer cfDNA assay was conducted to
148 identify the somatic mutations present in the primary tumor tissue in all cases; in two cases
149 additional biopsies from metastatic and recurrent disease were also sequenced for cases 5 and 9
150 respectively. At least 1 somatic hotspot mutation at an arbitrary cut-off of ≥20% VAF was
151 detected in 9/13 (69%) patient tumors that was not present in the matched lymphocytes (Table
152 S2). In the other four cases, matched tumor and normal samples were sequenced using a whole
153 exome (WES) approach, then used to guide development of a custom targeted cfDNA panel
154 (Table S1). For details of the mutations detected in each patient and selected for custom ctDNA
155 panel design, see Table S2. Two of the patients sequenced using WES (patients 1 and 2) were
156 found to have an unusually high number of single nucleotide variants (SNVs) with 301 SNVs
157 and 131 SNVs in 37MB respectively; using MSIsensor, patient 1 was identified as MSI-H (5/5
158 markers positive) and patient 2 harboured a *POLE* p.G541E mutation of unknown significance,
159 but her primary tumor was MSS.

160

161 ***ctDNA can detect EC recurrence and progression earlier than scans***

162 The median lead time of ctDNA over radiological imaging or clinical recurrence in patients for
163 whom we had sample available prior to recurrence or progression was 2.5 months (n = 6, range
164 1 – 8 months) (Figure 1). ctDNA was detected in all four patients (100%) who were diagnosed
165 with stage I disease at diagnosis and who subsequently recurred (Figure 1, Table S2). For patient
166 1 the lead time of ctDNA over radiological imaging was 8 months and there was 16 months
167 between the first positive ctDNA and the patient developing symptoms (Figure 1). Two of the
168 stage I patients (cases 1 and 2) had serial samples analyzed and disease progression was
169 confirmed with increasing ctDNA levels in concordance with both clinical and imaging
170 progression (case 2). ctDNA was detected in the four patients (100%) who were diagnosed with
171 stage IV disease and had progressive disease on imaging (Figure 1, Table S2).



Figure 1: Summary of each patient's results of clinical imaging and results of serial samples in terms of detection of ctDNA. Asterisks above sample for patient 1 indicates mutation was present in IGV but not called due to high strand bias.

ctDNA accurately reflects EC disease kinetics during treatment

ctDNA levels accurately mirrored the radiological response of a patient undergoing chemotherapy treatment for recurrent EC, with a clonal *TP53* p.Y220C mutation becoming undetectable during treatment, before rising again prior to radiological progression (Figure 2). An additional two patients (cases 9 and 11) diagnosed with stage I EC received radiotherapy, one for a vaginal vault recurrence and the other as primary treatment, respectively. For case 11,

183 ctDNA was not detected in three plasma samples following primary radical radiotherapy, in
184 keeping with clinical findings of complete response (Figure 1). ctDNA was detected following
185 treatment of the vault recurrence (case 9 – Table S2); however, became negative with time and
186 remained negative, in keeping with clinical and radiological findings of complete resolution of
187 the recurrence and no ongoing disease.



188

189 **Figure 2:** Multiregional sampling from patient 5 alongside the respective variant allele
190 frequencies of the major driver mutation, *TP53* p.Y220C, identified in the primary tumor sample
191 (located in the endometrium), local metastatic lesion (located in the ovary) and the distal
192 metastatic lesion (located in the omentum). The levels of cfDNA and ctDNA in pre-treatment
193 and post-treatment plasma samples are shown in the accompanying left-hand graph, clearly
194 demonstrating a rise in ctDNA levels 3 months prior to radiological relapse (right-hand).
195 *samples analyzed exclusively by ddPCR. Grey shaded area indicates treatment with carboplatin
196 and paclitaxel. PR = Partial response; RP = radiological progression.

197

198 ***Follow-up of high-risk EC cases***

199 In the three cases with high-risk EC at diagnosis (stage III non-endometrioid histology) ctDNA
200 as detected in only one case (Patient 13 - Figure 1, Table S2). All patients were alive at the
201 consensus date with no clinical or radiological sign of recurrence and continue to be followed-
202 up.

203

204 ***Longitudinal ctDNA can detect acquired microsatellite instability***

205 Only one patient's tumor (case 1) was classified as MSI-H with all five markers displaying
206 microsatellite instability, which was confirmed using ctDNA (3/5 markers positive – BAT25,
207 NR-24 and NR-27) (Figure 3A). In addition, ctDNA was able to identify the acquisition of
208 microsatellite instability in a case (case 2) whose primary tumor was microsatellite stable (MSS).
209 The patient had received adjuvant chemotherapy but had subsequently recurred. Longitudinal
210 samples revealed the acquisition of MSI-H status, with two of the five markers (NR-24 and NR-
211 27) displaying MSI in the last plasma sample (Figure 3B, Table S2).

		Examined microsatellite loci				
		BAT-25	BAT-26	NR-21	NR-24	NR-27
Patient 1	Primary tumor	●	●	●	●	●
	Plasma 1	○	○	○	○	○
	Plasma 2	○	○	○	○	○
	Plasma 3	○	○	○	○	●
	Plasma 4	○	○	○	○	●
	Plasma 5	○	○	○	○	○
	Plasma 6	●	○	○	●	●
Patient 2	Primary tumor	○	○	○	○	○
	Plasma 1	○	○	○	○	○
	Plasma 2	○	○	○	○	○
	Plasma 3	○	○	○	▲	▲

212

213 **Figure 3:** Microsatellite status in the primary tumors and longitudinal plasma samples of patients
214 1 (MSI-H) and 2 (MSS). ○ = alleilic shift not detected, ● = alleilic shift detected,
215 ▲ = alleilic shift has changed from negative to positive.
216
217 ***ctDNA is reflective of EC tumor heterogeneity and evolution***
218 Analysis of the primary, metastatic and recurrent tumor biopsies and matched plasma DNA for
219 two cases (cases 5 and 9) demonstrated that mutations identified in biopsies from different
220 locations were present in the ctDNA but that additional mutations could also be identified.
221 Truncal *TP53* p.Y220C (case 5) and *PIK3CA* p.H1047R (case 9) mutations were identified in
222 primary and recurrent tumors but additional mutations, *MET* p.T1010I, *FGFR2* p.S252W and
223 *KRAS* p.G12A, were detected in the ctDNA at recurrence that were not present in the tumor
224 samples (Table S2).
225
226 **DISCUSSION**
227 We have shown that ctDNA is highly sensitive in identifying endometrial cancer recurrence in
228 different histological subtypes and grades, and have a lead time of up to 16 months over patient
229 reported symptoms and up to 8 months compared to imaging. In addition, we have shown that
230 ctDNA levels accurately reflect disease activity, with earlier identification of
231 response/progression than on CT imaging. We also report the first case of ctDNA identifying the
232 acquisition of microsatellite instability in a case of EC recurrence, an increasingly important
233 stratifying feature for determining optimum patient treatment.
234
235 Our results are in keeping with studies published in other tumor types and supports the clinical
236 utility of ctDNA in early detection of recurrence in endometrial cancer [15] and other solid
237 tumors [12, 13]. The use of different technologies for ctDNA detection has given further insight

238 into the optimum methods that can be taken forward for use in a clinical trial determining the
239 potential for this new development on patient management. We have shown a benefit in using
240 WES to profile the tumor tissue and tracking mutations with a customised targeted cfDNA panel
241 relative to using a driver gene approach, which did not identify any mutations in four tumor
242 samples, equating to approximately one third of our cohort who otherwise would not have been
243 monitored. Additionally, the customised targeted panel can give greater informative value in
244 monitoring of tumor evolution, identifying somatic variants not present in the primary tumor
245 tissue. This further highlights the beneficial value of using a targeted customised panel approach
246 over a driver gene approach as it may not elucidate the evolving genetic proportions as accurately
247 as the personalized approach.
248
249 At present there is no EC specific blood tumor marker to monitor for disease recurrence, unlike
250 CA125 and ovarian cancer. Our results have shown the potential of ctDNA to monitor patients
251 undergoing treatment, as compared to waiting for radiological response. Parkinson et al.,
252 reported that chemotherapy response for the treatment of high-grade serous ovarian cancer was
253 detected earlier with ctDNA, as compared to CA125, with a nadir of 37 days compared to 84
254 days respectively, and ctDNA was more prognostic than CT imaging [22]. Resistance to first
255 line chemotherapy for EC is known to be a greater issue than with ovarian cancer [23], and
256 should our results be replicated in a larger population it opens up the potential for ctDNA
257 identification of non-efficacious treatments at an earlier time point, rather than waiting for
258 imaging assessment of disease response.
259
260 Our results have also shown an additional benefit of longitudinal monitoring of patients using
261 personalized assays containing MSI markers with the discovery of acquired MSI-H status
262 through serial plasma sampling. ctDNA analysis has been shown to detect MSI [24], reflect

263 tumor heterogeneity [25] and to track tumor evolution [11]. Acquired MSI-H status has
264 previously been shown in prostate cancer [26] however, to our knowledge, this is the first report
265 of acquired MSI-H status in EC. The presence of a MMR gene deficiency is known to be
266 positively associated with response to PD-1 inhibitors [27] and the approval of Pembroluzumab
267 has the potential to benefit up to 30% of advanced EC patients [28, 29]. This has led to the
268 recommendation that all EC patients undergoing MSI testing [30]. Indeed, in the relapse setting,
269 the use of Pembrolizumab has been modeled to be cost-effective in MSI-H patients, as compared
270 to single agent pegylated liposomal doxorubicin or bevacizumab [31]. The identification of
271 acquired MSI mutations in relapsed EC highlights another population of patients who could
272 potentially benefit from a PD-1 inhibitor but who would not be eligible if their MSI status was
273 determined from their primary tumor alone. The ability of ctDNA to detect such tumor evolutions
274 through a test with high patient acceptability [32] and without the need for invasive biopsies or
275 surgery could further support the development of personalized patient management and
276 hopefully improved patient outcomes.
277
278 In conclusion, ctDNA monitoring is able to accurately monitor the activity of endometrial cancer
279 and diagnose recurrence. Further work is needed to determine the lead time and its ability to
280 identify local, as well as distant, recurrent disease.
281
282 **Author contribution**
283 E.L.M. and D.S.G designed the study, E.L.M., D.S.G., L.S. and D.N.G performed experiments,
284 analyzed data and wrote the manuscript; E.L.M., A.C., P.S., N.F., A.G., J.W. and C.K. conducted
285 informed consents and collected samples and clinical data; E.L.M and D.S.G supervised the
286 study.
287

Funding: This work was supported by a Hope Against Cancer/Leicester Precision Medicine Institute PhD studentship (DSG, ELM, DNG) in conjunction with the UK Department of Health on an Experimental Cancer Medicine Centre grant [C10604/A25151], Hope Against Cancer grant [RM60GO754] (EM) and Medical Research Council (MRC) Proximity to Discovery scheme award [MCPC17194]. This research used the ALICE and SPECTRE High Performance Computing Facilities at the University of Leicester.

Conflict-of-interest disclosure: Lee Silcock is employed by Nonacus Limited. ELM has received research grants from Hope Against Cancer and Intuitive Surgical for unrelated studies.

298 **References**

299 [1] Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, et al. Cancer
300 treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69:363-85.
301 [2] Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, et al. SEER Cancer Statistics
302 Review, 1975-2016. Bethesda, MD: National Cancer Institute; 2019.
303 [3] Makker V, Green AK, Wenham RM, Mutch D, Davidson B, Miller DS. New therapies for
304 advanced, recurrent, and metastatic endometrial cancers. Gynecol Oncol Res Pract. 2017;4:19.
305 [4] de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, et al. Adjuvant
306 chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer
307 (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.
308 Lancet Oncol. 2019;20:1273-85.
309 [5] Abbink K, Zusterzeel PL, Geurts-Moespot AJ, Herwaarden AEV, Pijnenborg JM, Sweep FC,
310 et al. HE4 is superior to CA125 in the detection of recurrent disease in high-risk endometrial
311 cancer patients. Tumour Biol. 2018;40:1010428318757103.
312 [6] Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, et al. Mutation tracking
313 in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med.
314 2015;7:302ra133.
315 [7] Guttery DS, Page K, Hills A, Woodley L, Marchese SD, Rghebi B, et al. Noninvasive
316 detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive
317 metastatic breast cancer. Clinical chemistry. 2015;61:974-82.
318 [8] Olsson E, Winter C, George A, Chen Y, Howlin J, Tang MH, et al. Serial monitoring of
319 circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic
320 disease. EMBO Mol Med. 2015;7:1034-47.
321 [9] Page K, Guttery DS, Fernandez-Garcia D, Hills A, Hastings RK, Luo J, et al. Next Generation
322 Sequencing of Circulating Cell-Free DNA for Evaluating Mutations and Gene Amplification in
323 Metastatic Breast Cancer. Clinical chemistry. 2017;63:532-41.
324 [10] Shaw JA, Page K, Blighe K, Hava N, Guttery D, Ward B, et al. Genomic analysis of
325 circulating cell-free DNA infers breast cancer dormancy. Genome research. 2012;22:220-31.
326 [11] Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, et al.
327 Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545:446-
328 51.
329 [12] Coombes RC, Page K, Salari R, Hastings RK, Armstrong A, Ahmed S, et al. Personalized
330 Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence. Clinical

331 cancer research : an official journal of the American Association for Cancer Research.
332 2019;25:4255-63.
333 [13] Reinert T, Henriksen TV, Christensen E, Sharma S, Salari R, Sethi H, et al. Analysis of
334 Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal
335 Cancer. JAMA Oncol. 2019.
336 [14] Bolivar AM, Luthra R, Mehrotra M, Chen W, Barkoh BA, Hu P, et al. Targeted next-
337 generation sequencing of endometrial cancer and matched circulating tumor DNA: identification
338 of plasma-based, tumor-associated mutations in early stage patients. Mod Pathol. 2019;32:405-
339 14.
340 [15] Pereira E, Camacho-Vanegas O, Anand S, Sebra R, Catalina Camacho S, Garnar-Wortzel
341 L, et al. Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment
342 Response and Survival In Gynecologic Cancers. PloS one. 2015;10:e0145754.
343 [16] Page K, Guttery DS, Zahra N, Primrose L, Elshaw SR, Pringle JH, et al. Influence of plasma
344 processing on recovery and analysis of circulating nucleic acids. PloS one. 2013;8:e77963.
345 [17] Shaw JA, Guttery DS, Hills A, Fernandez-Garcia D, Page K, Rosales BM, et al. Mutation
346 Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer
347 Patients with High Circulating Tumor Cell Counts. Clinical cancer research : an official journal
348 of the American Association for Cancer Research. 2017;23:88-96.
349 [18] Rimmer A, Phan H, Mathieson I, Iqbal Z, Twigg SRF, Consortium WGS, et al. Integrating
350 mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing
351 applications. Nature genetics. 2014;46:912-8.
352 [19] Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive
353 detection of somatic point mutations in impure and heterogeneous cancer samples. Nat
354 Biotechnol. 2013;31:213-9.
355 [20] Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from
356 high-throughput sequencing data. Nucleic acids research. 2010;38:e164.
357 [21] Niu B, Ye K, Zhang Q, Lu C, Xie M, McLellan MD, et al. MSIsensor: microsatellite
358 instability detection using paired tumor-normal sequence data. Bioinformatics. 2014;30:1015-6.
359 [22] Parkinson CA, Gale D, Piskorz AM, Biggs H, Hodgkin C, Addley H, et al. Exploratory
360 Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response
361 for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study. PLoS
362 Med. 2016;13:e1002198.

363 [23] Pectasides D, Xiros N, Papaxoinis G, Pectasides E, Sykiotis C, Koumarianou A, et al.
364 Carboplatin and paclitaxel in advanced or metastatic endometrial cancer. Gynecol Oncol.
365 2008;109:250-4.
366 [24] Georgiadis A, Durham JN, Keefer LA, Bartlett BR, Zielonka M, Murphy D, et al.
367 Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer
368 Patients Treated with PD-1 Blockade. Clin Cancer Res. 2019;25:7024-34.
369 [25] Namlos HM, Boye K, Mishkin SJ, Baroy T, Lorenz S, Bjerkehagen B, et al. Noninvasive
370 Detection of ctDNA Reveals Intratumor Heterogeneity and Is Associated with Tumor Burden in
371 Gastrointestinal Stromal Tumor. Mol Cancer Ther. 2018;17:2473-80.
372 [26] Abida W, Cheng ML, Armenia J, Middha S, Autio KA, Vargas HA, et al. Analysis of the
373 Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint
374 Blockade. JAMA Oncol. 2019;5:471-8.
375 [27] Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair
376 deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409-13.
377 [28] Ott PA, Bang YJ, Berton-Rigaud D, Elez E, Pishvaian MJ, Rugo HS, et al. Safety and
378 Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive
379 Endometrial Cancer: Results From the KEYNOTE-028 Study. J Clin Oncol. 2017;35:2535-41.
380 [29] Arend RC, Jones BA, Martinez A, Goodfellow P. Endometrial cancer: Molecular markers
381 and management of advanced stage disease. Gynecol Oncol. 2018;150:569-80.
382 [30] Barroso-Sousa R, Ott PA. PD-1 inhibitors in endometrial cancer. Oncotarget.
383 2017;8:106169-70.
384 [31] Barrington DA, Dilley SE, Smith HJ, Straughn JM, Jr. Pembrolizumab in advanced
385 recurrent endometrial cancer: A cost-effectiveness analysis. Gynecol Oncol. 2019;153:381-4.
386 [32] Relton A, Collins A, Guttery DS, Gorsia D, McDermott H, Moss EL. Patient acceptability
387 of ctDNA testing in endometrial cancer follow-up. 2019.
388
389
390
391
392
393
394

395 **Table 1:** Tumor characteristics and outcome of study cohort (n=13)

Patient	Histology	Stage at diagnosis	Recurrence	Site of recurrence	Outcome
1	Endometrioid G1	IB	Yes	Pelvic	Alive with disease
2	Endometrioid G3	IB	Yes	Distant	Died with disease
3	Serous	IA	Yes	Distant	Alive with disease
4	Endometrioid G1	IB	Yes	Pelvic, distant	Alive with disease
5	Endometrioid G3	IVB	Yes	Distant	Alive with disease
6	Endometrioid G2	IVB	Yes	Distant	Died with disease
7	Endometrioid G1	IVB	Yes	Distant	Alive with disease
8	Carcinosarcoma + Serous	IVB	Yes	Pelvic, distant	Alive with disease
9	Endometrioid G1	IA	Yes	Vaginal vault	Alive no disease
10	Endometrioid G1	I	No	NA	Died no disease
11	Serous	IIIC1	No	NA	Alive no disease
12	Clear Cell	IIIB	No	NA	Alive no disease
13	Carcinosarcoma	IIIA	No	NA	Alive no disease

396